Jason A. Sprowl PhD

Jason Sprowl

Jason A. Sprowl
PhD

Assistant Professor

Department of Pharmaceutical Sciences

School of Pharmacy


Specialty/Research Focus

Cancer Chemotherapy; Drug Delivery; Drug Targeting; Drug Transport; Drug Utilization Research; Drug-Drug Interactions; Pharmacodynamic; Pharmacogenetics; Pharmacogenomics; Pharmacogenomics; Pharmacokinetic; Pharmacokinetics; PK/PD; Toxicology; Translational Research

Contact Information
372 Kapoor Hall
Buffalo, NY 14214-8033
Phone: (716) 645-4849
Fax: 716-829-6569
jasonspr@buffalo.edu



Professional Summary:

Our research program conducts translational studies that seek to identify and characterize regulators of drug disposition that ultimately promote variability in the success of treatment or the severity of toxicities experienced by cancer patients. We currently focus on the role of transporter proteins in regulating drug or nutrient uptake and accumulation.

Education and Training:

  • Postdoctoral Fellow, Pharmaceutical Sciences, St. Jude Children‘s Research hospital (2014)
  • PhD, Biomolecular Sciences, Laurentian University (2010)
  • BS, Biochemistry, Laurentian University (2004)

Employment:

  • Assistant Professor, Pharmaceutical Sciences, University at Buffalo (2018-present)
  • Assistant Professor, Pharmaceutical, Social and Administrative Sciences, D'Youville College (2014–2018)

Awards and Honors:

  • Faculty Member of the Year - D‘Youville College, School of Pharmacy, Department of Pharmaceutical, Social and Administrative Sciences (2018)
  • Carl Jackson Postdoctoral Excellence Award (2014)
  • David Goldstein Trainee Award (2012)

Research Expertise:

  • Membrane Transporters: Role of transporters in regulating pharmacokinetics and pharmacodynamics of therapeutics. Membrane transporters as regulators of drug toxicity.

Patents:

  • TNF gene expression to assess response to taxanes or anthracyclines TNF-related gene expression used as a biomarker to measure response to taxanes or anthracycles (2014)

Journal Articles:

See all (11 more)

Professional Memberships:

  • American Society for Pharmacology and Experimental Therapeutics (ASPET) (2018–present)
  • Rho Chi Society (2018–present)
  • American Association of Colleges of Pharmacy (AACP) (2014–present)
  • American Society For Clinical Pharmacology and Therapeutics (ASCPT) (2011–2015)
  • American Association For Cancer Research (AACR) (2008–2015)

Presentations:

  • "Influence of Nilotinib and different Tyrosine Kinases on OATP1B1 Function" 2nd Annual Division of Pharmaceutics Scientific Retreat, The Ohio State University, Pharmaceutical Sciences (2017)
  • "OATP1B2-deficiency protects against paclitaxel-induced neuropathy" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2016)
  • "Identification of OAT1/OAT3 as contributors to cisplatin nephrotoxicity" American Association for Cancer Research Annual Meeting, American Association for Cancer Research (2015)
  • "Tyrosine phosphorylation is essential for OCT2 function and a target of inhibition by TKIs" American Association for Cancer Research Annual Meeting, American Association for Cancer Research (2015)
  • "Organic cation transporters mediate cisplatin and oxaliplatin side effects" International Conference of Anticancer Research, Anticancer Research (2014)
  • "Amelioration of oxaliplatin neurotoxicity by dasatinib" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2013)
  • "Conjunctive therapy of cisplatin with OCT inhibitors: influence on antitumor efficacy and systemic clearance" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2013)
  • "Identification of tyrosine kinase inhibitors as modulators of OCT2 function" EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, EORTC-NCI-AACR (2012)
  • "Association of ABCC2 polymorphisms with cisplatin disposition and efficacy" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2012)
  • "Contribution of p53 signaling to cisplatin nephrotoxicity in Oct1/Oct2-deficient mice" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2012)
  • "Oxaliplatin-induced peripheral neurotoxicity is dependent on OCT2-mediated transport" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2012)
  • "Role of the 1C aldo-keto reductases in resistance to doxorubicin in MCF-7 breast cancer cells" American Association for Cancer Research Annual Meeting, American Association for Cancer Research (2010)
  • "Resistance to TNFα in MCF-7 Cells during the acquisition of taxane resistance" American Association for Cancer Research Annual Meeting, American Association for Cancer Research (2009)
  • "Clustering of anthracycline-containing lysosomes in drug-resistant MCF-7 cells in response to tesmilifene" American Association for Cancer Research Annual Meeting, American Association for Cancer Research (2008)
  • "Role of promoter methylation in the induction of ABCB1 gene expression in anthracycline-resistant and paclitaxel-resistant breast tumor cells" American Association for Cancer Research Annual Meeting, American Association for Cancer Research (2008)
See all (5 more)

School News:

In the Media:


Clinical Specialties:

Clinical Offices:

Insurance Accepted:



Contact Information

372 Kapoor Hall
Buffalo, NY 14214-8033
Phone: (716) 645-4849
Fax: 716-829-6569
jasonspr@buffalo.edu